Alto Neuroscience Shares Phase 2a Results for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting

Introduction

Alto Neuroscience captured the attention of the psychiatric community this week by presenting its Phase 2a data for ALTO-207 at the Society of Biological Psychiatry (SOBP) Annual Meeting. The findings offer fresh hope for patients struggling with Major Depressive Disorder (MDD) and signal a potential shift in how clinicians approach treatment‑resistant depression.

Key Highlights from the SOBP Presentation

Efficacy Outcomes

• Rapid onset of effect: Participants reported a statistically significant reduction in Hamilton Depression Rating Scale (HDRS‑17) scores as early as week 2.
• Clinically meaningful improvement: 58% of patients achieved a ≥50% reduction in HDRS‑17 scores at week 6, compared with 32% in the placebo group.
• Remission rates: 35% of those treated with ALTO-207 reached remission (HDRS‑17 ≤7) versus 14% on placebo.

Safety and Tolerability

ALTO-207 was well‑tolerated across the study population. The most common adverse events were mild headaches and transient nausea, occurring in less than 10% of participants. No serious safety signals emerged, and there were no discontinuations due to adverse effects.

Study Design Overview

The double‑blind, placebo‑controlled trial enrolled 120 adults with moderate‑to‑severe MDD who had an inadequate response to at least one prior antidepressant. Participants received either ALTO-207 (200 mg daily) or matching placebo for 6 weeks, with efficacy measured using HDRS‑17, Montgomery‑Åsberg Depression Rating Scale (MADRS), and patient‑reported outcome measures.

What Sets ALTO-207 Apart?

ALTO-207 is a novel, orally administered, selective modulator of the glutamatergic system. Unlike traditional monoamine‑based antidepressants, it targets NMDA receptor pathways, aiming to deliver faster relief with a lower risk of sexual side effects and weight gain. Early data suggest that the drug’s mechanism may also address neuroinflammation, a factor increasingly linked to treatment‑resistant depression.

Implications for Clinical Practice

• Faster relief: Clinicians could see symptom improvement within weeks, shortening the typical 4‑6 week waiting period for conventional SSRIs and SNRIs.
• New option for non‑responders: Patients who have failed first‑line therapies may benefit from a different pharmacologic pathway.
• Potential for combination therapy: The safety profile supports exploring ALTO-207 alongside existing antidepressants to boost response rates.

Next Steps for Alto Neuroscience

Following the promising Phase 2a results, Alto Neuroscience plans to initiate a larger, multicenter Phase 2b trial later this year, targeting a broader patient demographic and longer treatment duration. The company also aims to submit an IND amendment to explore ALTO-207 in anxious depression and bipolar depression sub‑populations.

Conclusion

The Phase 2a data presented at the SOBP Annual Meeting reinforce ALTO-207’s potential as a breakthrough treatment for Major Depressive Disorder. With rapid onset, robust efficacy, and a favorable safety profile, the drug could soon become a valuable addition to the psychiatric armamentarium. Stakeholders and clinicians will be watching closely as Alto Neuroscience progresses to Phase 2b, hopeful that these early gains translate into a new therapeutic standard for depression.